JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

AZN

181.74

+3.09%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

AZN

181.74

+3.09%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

AZN

181.74

+3.09%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

AZN

181.74

+3.09%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

AZN

181.74

+3.09%↑

Inicio・Lista de Acciones・Eli Lilly and Co.
Search

Eli Lilly and Co.

Cerrado

SectorSanidad

1,125.18 4.16

Compra Fuerte

Precios actualizados 4 jun 2026, 19:59 UTC

ComprarVender

Resumen

Variación precio

24h

Actual

Mínimo

1082.46

Máximo

1139.71

Métricas clave

By Trading Economics

Ingresos

758M

7.4B

Ventas

507M

20B

P/B

Media del Sector

38.458

49.888

BPA

8.55

Rentabilidad por dividendo

0.56

Margen de beneficios

37.355

Empleados

50,000

EBITDA

971M

9.4B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+17.5% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.56%

2.38%

Próximas Ganancias

5 ago 2026

Fecha Próximo Dividendo

10 jun 2026

Próxima Fecha de Ex Dividendo

14 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

189B

965B

Apertura anterior

1121.02

Cierre anterior

1125.18

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

84 / 344 Clasificación en Healthcare

Eli Lilly and Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

20 may 2026, 14:24 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Buys Engage Biologics for Up to $202 Million

DJ

Leer

2 jun 2026, 04:01 UTC

Adquisiciones, fusiones, absorciones

M&A Is Back in a Big Way. These Are the Sectors in Play. -- Barrons.com

DJ

Leer

29 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

DJ

Leer

26 may 2026, 12:29 UTC

Adquisiciones, fusiones, absorciones

Lilly Agrees to Buy Trio of Vaccine Developers -- Update

DJ

Leer

26 may 2026, 10:35 UTC

Adquisiciones, fusiones, absorciones

Eli Lilly Agrees to Acquire Three Vaccine Developers, Company Says -- WSJ

DJ

Leer

26 may 2026, 10:35 UTC

Adquisiciones, fusiones, absorciones

Lilly's Deals Are Worth up to Nearly $4 Billion Combined, Company Says -- WSJ

DJ

Leer

26 may 2026, 10:35 UTC

Adquisiciones, fusiones, absorciones

Lilly to Acquire Curevo, LimmaTech and Vaccine Co., Company Says -- WSJ

DJ

Leer

26 may 2026, 10:35 UTC

Adquisiciones, fusiones, absorciones

Lilly Agrees to Buy Trio of Vaccine Developers -- WSJ

DJ

Leer

20 may 2026, 13:35 UTC

Adquisiciones, fusiones, absorciones

Engage Bio: Eli Lilly Deal Includes Upfront, Milestone Payments >LLY

DJ

Leer

20 may 2026, 13:34 UTC

Adquisiciones, fusiones, absorciones

Engage Bio Acquired by Eli Lilly for Up to $202 Million >LLY

DJ

Leer

7 may 2026, 09:30 UTC

Ganancias

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

DJ

Leer

6 may 2026, 12:36 UTC

Ganancias

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

DJ

Leer

6 may 2026, 10:12 UTC

Ganancias

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

DJ

Leer

6 may 2026, 09:58 UTC

Ganancias

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

DJ

Leer

30 abr 2026, 20:59 UTC

Acciones populares

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

DJ

Leer

30 abr 2026, 20:12 UTC

Ganancias

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

DJ

Leer

30 abr 2026, 16:43 UTC

Ganancias

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

DJ

Leer

30 abr 2026, 16:10 UTC

Charlas de Mercado

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

DJ

Leer

30 abr 2026, 15:13 UTC

Ganancias

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

DJ

Leer

30 abr 2026, 14:58 UTC

Ganancias

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

DJ

Leer

30 abr 2026, 14:53 UTC

Ganancias

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

DJ

Leer

30 abr 2026, 14:50 UTC

Ganancias

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

DJ

Leer

30 abr 2026, 14:42 UTC

Ganancias

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

DJ

Leer

30 abr 2026, 14:39 UTC

Ganancias

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

DJ

Leer

30 abr 2026, 14:35 UTC

Ganancias

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

DJ

Leer

30 abr 2026, 14:24 UTC

Ganancias

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

DJ

Leer

30 abr 2026, 14:17 UTC

Ganancias

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

DJ

Leer

30 abr 2026, 13:56 UTC

Ganancias

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

DJ

Leer

30 abr 2026, 13:37 UTC

Acciones populares

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

DJ

Leer

30 abr 2026, 12:32 UTC

Charlas de Mercado
Ganancias

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

DJ

Leer

Comparación entre iguales

Cambio de precio

Eli Lilly and Co. previsión

Precio Objetivo

By TipRanks

17.5% repunte

Estimación a 12 Meses

Media 1,267.57 USD  17.5%

Máximo 1,500 USD

Mínimo 850 USD

De acuerdo con 23 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Eli Lilly and Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

23 ratings

20

Comprar

2

Mantener

1

Vender

De acuerdo con 23 analistas que ofrecen calificaciones bursátiles a para Eli Lilly and Co. Dist en los últimos 3 meses.

Sentimiento

By Acuity

84 / 344 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Otras acciones del sector

JNJ

Johnson and Johnson

228.23

↑ +2.11%

ABBV

AbbVie Inc

224.88

↑ +3.55%

UNH

UnitedHealth Group Inc

396.79

↑ +4.98%

MRK

Merck & Co Inc.

120.25

↑ +4.69%

AZN

AstraZeneca PLC

181.74

↑ +3.09%